The ATS 2025 International Conference offers a robust scientific program highlighting cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several Postgraduate Courses, Scientific Symposia, and Meet the Expert Sessions addressing new developments and considerations in cellular and molecular biology, as listed below. A curated list of clinical and scientific sessions related to these topics is also available on the ATS365 platform. For more information on these and other sessions to be presented May 16–21 in San Francisco, visit the online Advance Program.
- A103 MOVING TOWARDS PRECISION SEPSIS CARE: FROM THE BENCH TO THE BEDSIDE
- A107 NOVEL THERAPIES AND MOLECULAR PATHWAYS IN COPD, AATD, AND AIRWAY REGENERATION
- A108 ALL THAT’S WICKED IN ASTHMA
- A11 CENTENNIAL CELEBRATION OF VA’S RESEARCH AND DEVELOPMENT PROGRAM
- A16 BEYOND THE DUST: ADVANCING EXPOSURE ASSESSMENT, METABOLOMICS, AND TREATMENT IN OCCUPATIONAL LUNG DISEASES
- A19 COMING INTO FOCUS: NOVEL APPROACHES TO CAPTURE ASTHMA
- A21 UNCOVERING THE IMMUNE LANDSCAPE AND MOLECULAR DRIVERS OF LUNG CANCER: FROM CARCINOGENESIS TO TARGETED THERAPIES
- A22 BREAK ON THROUGH: AIRWAY EPITHELIAL BARRIER IN INFLAMMATION AND INJURY
- A23 MICROBIAL MAESTROS: ORCHESTRATION OF HOST-PATHOGEN INTERACTION
- A30 BIOMARKERS, PREDICTORS, AND MODIFIERS OF PEDIATRIC PULMONARY OUTCOMES
- A31 THE EVOLVING LANDSCAPE OF BRONCHOPULMONARY DYSPLASIA: MAKING STRIDES
- A64 EVALUATION AND TESTING FOR PEDIATRIC LUNG DISEASES
- A69 EMERGING MOLECULAR PATHWAYS IN ACUTE LUNG INJURY AND PULMONARY INFLAMMATION
- A70 GENE EXPRESSION, METABOLISM AND EPITHELIAL DYSFUNCTION IN AIRWAY DISEASES: FROM ASTHMA TO COPD
- A71 EPITHELIAL DYSFUNCTION, INFLAMMATION AND CIGARETTE SMOKE: DRIVERS OF COPD AND CF PATHOGENESIS
- A72 KNIVES OUT: SHARPENING TOOLS FOR UNDERSTANDING ASTHMA AND OTHER AIRWAY DISEASES
- A74 FIBROTIC LUNG DISEASE REVISITED
- A76 FINGER ON THE PULSE: CARDIOPULMONARY DYSFUNCTION IN LUNG DISEASE
- A8 EMPHYSEMA ACROSS DISEASES: FLAWED (RE)GENERATION OR RAPID DESTRUCTION?
- A88 EPIGENETICS: HOW EARLY LIFE EXPOSURES CONTRIBUTE TO LUNG DISEASE LATER IN LIFE
- A9 ADVANCING HOST-DIRECTED THERAPIES IN PULMONARY INFECTIONS: BRIDGING RESEARCH AND CLINICAL PRACTICE
- A93 BREATH OF HOPE: DECODING LUNG INJURY AND UNLOCKING TREATMENTS
- A98 EARLY EXPOSURES, LASTING IMPACTS: HOW PRENATAL AND CHILDHOOD EXPOSURES SHAPE RESPIRATORY HEALTH
- A99 ENDOTHELIAL DYNAMICS: INJURY, IMMUNITY AND THERAPEUTIC INNOVATIONS
- B104 UNMASKING MECHANISMS OF EXPOSURE-RELATED INFLAMMATION AND LUNG DISEASE
- B105 PULMONARY FUNCTION TESTING, IMAGING, AND DIAGNOSTIC TOOLS FOR PEDIATRIC PULMONARY DISEASES
- B108 INNOVATIVE INSIGHTS INTO LUNG INJURY: FROM INFLAMMATION TO BARRIER RESTORATION
- B15 MACROPHAGES: THE PAC-MAN OF THE IMMUNE SYSTEM
- B18 BEST IN PEDIATRICS
- B28 TRANSCRIPTIONAL AND MOLECULAR SIGNATURES IN PULMONARY FIBROSIS: PATHOGENESIS AND NOVEL INTERVENTIONS
- B29 AIRWAY AND ALVEOLAR EPITHELIAL RESPONSES: FROM INJURY MECHANISMS TO REGENERATIVE POTENTIAL
- B30 ADVANCED MODALITIES TO UNCOVER PATHOPHYSIOLOGIC FEATURES IN COPD
- B5 REMINISCENCE OF AN EARLIER LIFE – SHEDDING MECHANISTIC LIGHT ON THE TRANSGENERATIONAL IMPACT OF CIGARETTE SMOKE ON LUNG FUNCTION
- B59 SILENT ASSAULTS: LUNG DISEASE AND INFLAMMATION FROM DUST, FIRES, BLASTS, MILITARY DEPLOYMENT, AND THE WTC COLLAPSE
- B6 PRECISION MEDICINE IN SEVERE ASTHMA: LATE-BREAKING RESULTS FROM THE PRECISE TRIAL
- B66 BRONCHOPULMONARY DYSPLASIA AND CONGENITAL CARDIORESPIRATORY DISEASES
- B74 ADVANCED MODELS AND MOLECULAR SIGNATURES FOR UNDERSTANDING AND TREATING PULMONARY FIBROSIS
- B75 TARGETING CELLULAR SENESCENCE, IMMUNE DYSREGULATION, AND METABOLISM IN LUNG INJURY AND FIBROSIS
- B77 COMPLICATIONS IN LUNG TRANSPLANTATION
- B85 OBSTRUCTIVE AIRWAY AND LUNG DISEASE BEGINS IN THE WOMB
- B86 PULMONARY HYPERTENSION: UNRAVELING CELLULAR PHENOTYPE SHIFTS ACROSS THE TIMELINE OF DISEASE PROGRESSION
- B98 CELLULAR INTERACTIONS AND SIGNALING NETWORKS IN PULMONARY FIBROSIS
- B99 IDENTIFYING SIGNATURES OF DYSFUNCTION IN COPD
- C100 MORNING SHOWS THE DAY: PERINATAL DETERMINANTS OF AIRWAY STRUCTURE AND FUNCTION
- C109 IMMUNE AND CELLULAR MECHANISMS DRIVING AIRWAY DISEASES: FROM INFLAMMATION TO METABOLISM
- C110 BEYOND THE GOLDEN GATE: INNOVATIVE BIOMARKERS IN LUNG CANCER DIAGNOSIS, PROGNOSIS, AND TREATMENT
- C15 ‘OMICS ODYSSEY ACROSS LUNG DISEASES
- C18 SPATIAL AND SINGLE-CELL ANALYSIS OF LUNG DISEASE: BRIDGING EARLY MECHANISMS TO THERAPEUTIC GAPS
- C19 UNCOVERING DEEP ROOTS: NEW MECHANISMS IN AIRWAY DISEASE
- C2 TYPE 2 INFLAMMATION IN COPD: A PRO AND CON DEBATE
- C27 GENETICS AND -OMICS TO PREDICT AND UNDERSTAND CHILDHOOD LUNG DISEASES
- C29 READING BETWEEN THE LINES IN INTERSTITIAL LUNG DISEASE
- C30 HYPOXIC HORIZONS: UNRAVELING EPIGENETICS, CARDIOMETABOLIC FINDINGS AND MICROPLASTICS IN MURINE MODELS
- C36 ICU PRACTICE MAKES PERFECT: POLICIES, PHARMACOLOGY, AND EDUCATION
- C37 ADVANCING ARDS SCIENCE: FROM THE BENCH TO THE BEDSIDE
- C55 EXPOSED: INJURY AND CANCER FROM VAPING, MARIJUANA, SMOKE, AND WORKPLACE HAZARDS
- C6 TARGETING MYELOID IMMUNE RESPONSES IN THE LUNG TUMOR MICROENVIRONMENT FOR CANCER THERAPY
- C73 ENVIRONMENTAL STRESSORS AND MOLECULAR MECHANISMS DRIVING LUNG INJURY AND DISEASE PATHOGENESIS
- C74 CELLULAR DYNAMICS, ECM REGULATION, AND INNOVATIVE MODELS IN LUNG PATHOBIOLOGY
- C75 COPD: STRUCTURE AND FUNCTION
- C8 THE LIVER-LUNG AXIS IN PULMONARY VASCULAR DISEASE: BENCH TO BEDSIDE
- C88 YES, A WHOLE SESSION ON MUCUS: LATEST RESEARCH INSIGHTS
- C89 FROM AIR TO AILMENTS: UNDERSTANDING THE IMPACT OF AIRBORNE POLLUTANTS AND PARTICULATE MATTER FROM DIFFERENT SOURCES ON HEALTH
- C9 MANY FACES OF ALVEOLAR TYPE II CELLS- PLASTICITY IN HEALTH AND DISEASE
- C90 EARLY STAGES OF TUBERCULOSIS INFECTION: UPDATES ON AN EVER-CHANGING PARADIGM
- C94 BREATHING EASY: UNRAVELING THE MYSTERIES OF ASTHMA THROUGH TRANSLATIONAL STUDIES
- C97 CUTTING-EDGE ADVANCES IN PEDIATRIC LUNG DISEASES: FROM PREDICTION TO MANAGEMENT
- C99 THE ALVEOLAR NICHE AND EPITHELIAL REMODELING IN EARLY AND ADVANCED FIBROSIS
- D10 INSIGHTS INTO ACUTE LUNG INJURY REVEALED THROUGH LUNG TRANSPLANTATION
- D101 DISCOVERY OMICS AND COMPUTATIONAL STRATEGIES IN LUNG DISEASE RESEARCH
- D108 CELLULAR FATE, HOST-PATHOGEN INTERACTIONS, AND ENVIRONMENTAL INFLUENCES IN AIRWAY DISEASE
- D11 LONG-TERM CONSEQUENCES OF RESPIRATORY VIRAL INFECTIONS AND CHRONIC PULMONARY DISEASES: LONG-COVID, ASTHMA, ILD AND LUNG TRANSPLANT
- D12 GUARDIAN OF THE AIRWAYS: UNVEILING THE ROLE OF EPITHELIUM IN IMMUNE REGULATION
- D17 MITOCHONDRIAL AND EPITHELIAL DYNAMICS IN CHRONIC AND ACUTE LUNG DISEASE
- D18 CLEARING THE WAY: OPTIMIZING THERAPIES FOR MUCOCILIARY DISEASES
- D26 CLOUDED CONSEQUENCES: UNRAVELING THE MECHANISMS AND HEALTH EFFECTS OF VAPING AND E-CIGARETTES
- D27 CELLULAR MECHANISMS AND IMMUNE PATHWAYS UNDERLYING PEDIATRIC PULMONARY DISEASES
- D29 FROM BENCH TO BEDSIDE: UNRAVELING PULMONARY FIBROSIS THROUGH CELLULAR COMMUNICATION AND MOLECULAR PATHWAYS
- D5 RACE &GENETIC ANCESTRY: RELATIONSHIPS BETWEEN A SOCIAL CONSTRUCT AND BIOLOGY
- D85 RESPIRATORY MANIFESTATIONS OF ANCA-ASSOCIATED VASCULITIS: LESSONS FROM RECENTLY COMPLETED RCTS
- D96 PNEUMONIA’S SECRET RECIPE: A PINCH OF MICROBIOME, A DASH OF HOST FACTORS, AND A SHOT OF VACCINE
- D97 IMMUNE-EPITHELIAL INTERACTIONS AND LUNG REPAIR IN INJURY AND REPAIR
- D98 TRACING THE SCAR IN INTERSTITIAL LUNG DISEASES
- MD1 RED JOURNAL IN ACTION 1: EARLY CAREER LUNG RESEARCH HIGHLIGHTS
- MD10 NEUTROPHILIC MECHANISMS OF INFLAMMATION, INJURY, AND REPAIR IN LUNG DISEASES
- MD11 COPDGENE: A 15-YEAR LONGITUDINAL STUDY UNRAVELING COPD PROGRESSION AND HEALTH OUTCOMES
- MD12 LUNGMAP PHASE 3- NOVEL TECHNOLOGY, DATA SCIENCE, AND RESOURCES
- MD16 RED JOURNAL IN ACTION 2: AIRWAYS MEET NEUROSCIENCE PERSPECTIVES
- MD21 50 YEARS OF SUPPORTING LUNG RESEARCH: THE PARKER B. FRANCIS FELLOWSHIP
- MD22 EVALUATING INTERSTITIAL LUNG ABNORMALITIES AS EARLY RISK FACTORS FOR PULMONARY FIBROSIS
- MD23 NEW INSIGHTS INTO THE PATHOPHYSIOLOGY OF SEVERE ASTHMA
- MD25 INSIGHTS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD STUDY (SPIROMICS ) FAMILY OF STUDIES: EARLY DATA AND FUTURE PLANS
- MD28 HOW DO SHORT-LIVED LUNG INFECTIONS LEAD TO LONG-LASTING LUNG DAMAGE AND CHRONIC DISEASES?
- MD30 MICRO AND NANOPLASTICS HEALTH EFFECTS: WHAT WE KNOW OR DON’T
- MD31 LUNGMAP PHASE 3- HIGH RESOLUTION MOLECULAR PROFILING OF LUNG DISEASES
- MD35 UPDATES ON ARDS, PNEUMONIA, AND SPESIS PHENOTYPING CONSORTIUM
- MD5 NOVEL THERAPEUTIC TARGETS FOR PULMONARY ATERIAL HYPERTENSION (PAH)
- MD7 CARDIOPULMONARY FAILURE IN COPD: INSIGHTS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD AND HEART FAILURE STUDY (SPIROMICS HF)
- MTE29 ARTIFICIAL INTELLIGENCE AND THE FUTURE OF PULMONARY MEDICINE
- MTE4 BRONCHIECTASIS – MORE THAN A CASE OF CHRONIC COUGH
- MTE5 THE EVALUATION OF RECURRENT PULMONARY INFECTIONS: IDENTIFICATION OF PRIMARY IMMUNODEFIENCY AND DIFFERENTIAL DIAGNOSIS
- MTE6 HITCHHIKER’S GUIDE TO NAVIGATING SINGLE CELL RNA SEQUENCING: CRITICAL INSIGHTS FOR USERS
- PG13 LUNG IMMUNITY AND RESPIRATORY INFECTION
- PG14 UPDATES ON LUNG TRANSPLANTATION: WHAT PULMONOLOGISTS NEED TO KNOW
- PG8 INNOVATIVE PRECLINICAL MODELS FOR HUMAN LUNG RESEARCH: BRIDGING THE GAP FROM BENCH TO BEDSIDE
Register Today for ATS 2025
Register today for the ATS 2025 International Conference! Don’t miss the opportunity to experience this year’s premier respiratory health conference, May 16-21 in San Francisco. Join your colleagues to learn about the latest pulmonary, critical care, and sleep medicine developments. Not an ATS member? Join today and save on your conference registration!